Transient elevation of serum prolactin frequently follows generalised tonicclonic and complex partial seizures. However, the levels of prolactin during status epilepticus are not increased above the normal range. Exhaustion of central prolactin supplies has been proposed as a possible mechanism for the absence of prolactin increase during status epilepticus. To test this hypothesis we injected intravenous metoclopramide (10 mg) in eight consecutive patients with status epilepticus. One patient had generalised tonic-clonic status epilepticus. Seven patients had EEG-verified non-convulsive status epilepticus, consisting of one typical absence status, one atypical absence status and five complex partial status epilepticus. Metoclopramide raised the mean (SD) prolactin levels at least fivefold in all patients, from 5-8 (8.0) .ugl to 87-0 (39.0) ugIl, within 60 minutes after the injection. Thus the mechanism for low prolactin values in status epilepticus is not cellular depletion of stored prolactin, but more likely an altered regulation, presumably induced by prolonged seizure activity.
,ug/l and mean (SD) peak prolactin levels after metoclopramide were 87-0 (39 0) pg/l. There was no obvious difference between the various types of status in the response to metoclopramide. One patient was studied twice with two separate episodes of status, on the first occasion before, and on the other after treatment with diazepam. The prolactin responses to metoclopramide were similar. In three patients the effect of metoclopramide was studied also under baseline conditions. The values obtained after at least 24 hours without seizures did not differ from the responses in connection with status. Two patients (5 and 6) were without anticonvulsant medication at the time of the status, but at the time the baseline values were obtained they were under treatment with carbamazepine in steady-state.
Discussion
Knowledge of the regulation of prolactin under physiological conditions is incomplete. Two major factors, prolactin-inhibiting factor and prolactin-releasing factor, regulate prolactin secretion. The chemical identities of the prolactin-inhibiting factor and to prolactin-releasing factor still need to be clarified. In contrast to other pituitary hormones, the neuroendocrine control of prolactin is predominantly inhibitory. The major physiologic inhibitor appears to be dopamine, but gamma-aminobutyric acid has been suggested to be a part of nondopamine prolactin-inhibiting factor."5 16 Thyrotropin-releasing hormone and vasoactive intestinal polypeptide have been suggested as a prolactin-releasing factor." The temporary increase in serum prolactin after single seizures may be due to spread of abnormal electrical activity to areas of the central nervous system that regulate prolactin release.3 The seizure activity is presumed either to suppress the prolactin-inhibiting factor or to stimulate the prolactin-releasing factor.
It 25 or to be unaltered26 27 during treatment with anticonvulsant drugs. Monotherapy seemed to have less effect than polytherapy.22 Six of our eight patients were on monotherapy, and two patients were without medication since status epilepticus was their first manifestation of epilepsy. However, when the latter were given metoclopramide on a second occasion they were both on medication with carbamazepine. Ictal and baseline responses to metoclopramide did not differ in these two patients. Thus medication with antiepileptic drugs did not apparently influence our results.
The mechanisms behind the finding of prolactin levels not different from baseline values in association with status epilepticus remain obscure. Our results suggest that mechanisms other than cellular depletion of prolactin must be involved.
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